SEPN
Septerna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$36.38
+0.08%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +57.3%
- EBIT
- +57.4%
- EPS
- +75.2%
- Free cash flow
- +226.6%
- Operating cash flow
- +230.2%
Forward estimates
Based on analyst estimates
- Revenue
- -2.2%
- EBITDA
- -83.2%
- EPS
- —
Three-year CAGR
- Revenue
- +1644.5%
- EBITDA
- +33.3%
- EBIT
- +0.0%
- Net income
- +31.9%
- EPS
- +43.0%
- Free cash flow
- +257.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026